Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...

cosentyx article Cosentyx is the first and only fully-human interleukin-17A (IL-17A) antagonist. In the SCALP study, patients with moderate to severe psoriasis lesions of the scalp (n=102) were ...

Among its dozen FDA approvals for a variety of autoimmune disorders, AbbVie’s Humira has plenty of competition in most of its indications. In the debilitating skin condition hidradenitis suppurativa ...

Novartis’ interleukin-17A (IL-17A) Cosentyx (secukinumab) demonstrated early synovitis reduction in patients with active psoriatic arthritis in the phase IIIb ULTIMATE study. Synovitis, or joint ...

Novartis NVS has announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) adopted a positive opinion for the label expansion of blockbuster ...

Please provide your email address to receive an email when new articles are posted on . This approval makes Cosentyx the first interleukin-17A inhibitor and second biologic approved for hidradenitis ...

The digital press release with multimedia content can be accessed here: Basel, March 06, 2017 - Novartis announced today a new analysis showing that moderate-to-severe psoriasis patients treated with ...

Beating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting drugs in the immunology market, but Novartis’ Cosentyx has just fallen short on ...

Novartis has unveiled trial results which it says show that Cosentyx is the first and only IL-17A inhibitor to potentially modify the course of psoriasis. Novartis has unveiled trial results which it ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

Novartis’ Cosentyx is in a heated contest with Eli Lilly’s Taltz for IL-17A inhibitor supremacy, duking it out in three indications. Now, with new phase 3 data in spondyloarthritis, Novartis wants to ...

The FDA has approved Cosentyx® (secukinumab; Novartis) for the treatment of adults with active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. The Food and ...